Covid19
SaNOtize bags $24M to fund phase 3 trial of COVID-19 nasal spray – Fierce Pharma
.jpg?VersionId=y40pOgHNIxN93yk4mMXeyhybkRzAHbZP)
SaNOtize has raised $24 million, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial of its nitric oxide nasal spray.
SaNOtize has raised $24 million, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial of its nitric oxide nasal spray.
